A Phase 1, First-in-man, Multicenter, Open-label, Dose-escalation Study of Single-agent GBR 1302 in Subjects With HER2 Positive Cancers
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2018
At a glance
- Drugs GBR 1302 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Glenmark Pharmaceuticals S.A.
- 24 Jan 2018 According to Glenmark Pharmaceuticals media release, preliminary biomarker findings will be presented at the ASCO-SITC Clinical Immuno-Oncology Symposium 2018. Martin Wermke is a lead study investigator.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 28 Apr 2017 Planned number of patients changed from 30 to 60.